Highlights

• Optiscan Imaging lodged an InSpecta regulatory dossier with the FDA’s Centre for Veterinary Medicine on 31 March 2026 and launched the device in the US veterinary market on 7 July 2026.

• The company is targeting FDA 510(k) submissions for its InVue surgical and InForm pathology devices during the second half of calendar 2026.

• Optiscan reported revenue of A$339,227 for the half year ended 31 December 2025, while the net loss widened to A$3.40 million.

• Cash stood at A$15.13 million at 31 March 2026, supported by a A$1.69 million R&D tax refund received in May 2026.

• Optiscan Imaging shares closed at A$0.15 on 28 July 2026, declining A$0.005 or 3.23% during the session.

Optiscan Imaging Limited (ASX:OIL) is progressing its commercialisation strategy as the company advances multiple products based on its confocal laser endomicroscopy technology. The Melbourne-based medical device developer is working towards expanding its technology from research applications into clinical and veterinary markets.

The company’s core technology uses miniaturised laser microscopy to capture cellular-level images of living tissue in real time, often described as an optical biopsy approach. Unlike conventional biopsy procedures that require tissue removal and laboratory processing, the technology aims to provide immediate visual assessment during procedures.

After decades focused largely on research applications, Optiscan is now seeking to commercialise its platform through multiple product pathways, including veterinary imaging, surgical applications and pathology solutions.

InSpecta Launch Creates First Commercial Opportunity

On 31 March 2026, Optiscan submitted a regulatory dossier for InSpecta to the US FDA’s Centre for Veterinary Medicine, moving the product into formal review.

The company did not disclose a regulatory decision timeline, submission classification or expected approval date. However, Optiscan described the process as an important step in establishing a regulatory framework that could support future product submissions.

On 7 July 2026, Optiscan launched InSpecta into the US veterinary market, introducing the device at the American Veterinary Medical Association convention held in California.

The company has not disclosed pricing, distributor arrangements or commercial sales targets for InSpecta. The product represents Optiscan’s first move into a direct commercial market beyond research applications.

Human Healthcare Pipeline Progresses Towards FDA Submissions

Alongside its veterinary expansion, Optiscan continues advancing its human healthcare products.

The company’s InVue surgical imaging device and InForm pathology device are being developed for applications including cancer surgery and tissue assessment.

In July 2026, Optiscan announced progress across two clinical research programs:

  • A stage-two first-in-human head and neck cancer study at St John of God Murdoch Hospital in Perth commenced ahead of schedule after completion of initial stage-one cases.
  • A research agreement with Mayo Clinic was signed for a 35-patient breast-conserving surgery study in the United States.

The studies are designed to generate clinical evidence supporting potential FDA 510(k) submissions targeted for the second half of calendar 2026.

A 510(k) submission is the FDA pathway used for medical devices seeking clearance based on substantial equivalence to an existing marketed device. However, clearance depends on regulatory review and acceptance of supporting evidence.

Understanding Optiscan’s Technology Platform

Optiscan’s strategy centres around adapting its confocal laser endomicroscopy platform across different applications.

The company’s key products include:

  • InVue: A surgical imaging device designed to provide real-time tissue assessment during procedures.
  • InForm: A pathology-focused device intended to analyse removed tissue samples.
  • InSpecta: A veterinary imaging platform launched in the US market.
  • InVivage: An oral and dental application currently in preclinical development.
  • ViewnVivo: A research-focused instrument that has historically generated revenue.

The company has identified future opportunities across areas such as robotic surgery, telepathology and gastrointestinal applications. However, these remain longer-term development targets rather than current commercial commitments.

Optiscan’s partnerships with Mayo Clinic and Australian Clinical Labs remain important elements of its clinical development strategy, although neither relationship has been disclosed as generating material revenue.

Financial Position Reflects Development-Stage Business Model

Optiscan remains a development-stage medical technology company with spending significantly ahead of current revenue generation.

For the half year ended 31 December 2025, revenue from ordinary activities declined 43% to A$339,227, primarily due to lower ViewnVivo sales as research funding conditions weakened in some markets.

The company reported a net loss after tax of A$3.40 million, representing a 43% increase compared with the prior corresponding period.

The March 2026 quarterly report showed customer receipts of A$153,000 for the quarter and A$669,000 for the nine months ended March 2026.

Net operating cash outflow was A$2.42 million during the March quarter, taking nine-month operating cash outflows to A$6.55 million.

Cash at 31 March 2026 was A$15.13 million, while a A$1.69 million R&D tax refund received in May 2026 provided additional financial support.

The company previously completed an entitlement offer in August 2025, raising approximately A$17.75 million to support its development programs.

Why InSpecta Could Be Important for Growth

The veterinary market provides Optiscan with an opportunity to commercialise its technology in a potentially less complex environment compared with human healthcare.

Veterinary applications generally do not face the same reimbursement challenges as human medical devices, potentially allowing faster adoption if clinicians see value from real-time imaging capabilities.

However, commercial execution remains critical. Optiscan has not disclosed distribution agreements, pricing structures or sales targets, making the size and pace of the opportunity difficult to assess.

The larger long-term opportunity remains linked to human healthcare applications, particularly InVue and InForm, where regulatory clearance and clinical adoption will determine commercial potential.

Potential Growth Catalysts

• FDA feedback or regulatory progress regarding the InSpecta dossier submitted in March 2026.

• Submission of InVue and InForm FDA 510(k) applications targeted for the second half of calendar 2026.

• First commercial revenue from InSpecta sales or veterinary partnerships.

• Progress updates from the Mayo Clinic breast study and head and neck cancer clinical program.

• Further expansion of commercial partnerships supporting adoption of Optiscan technology.

Risks and Challenges

Optiscan’s primary challenge remains converting advanced technology into sustainable commercial revenue. While the company has progressed several regulatory and clinical milestones, revenue generation remains limited compared with ongoing research and development expenditure.

The company’s cash position provides funding capacity, but commercial expansion, regulatory activities and product launches may increase expenditure requirements.

Regulatory approval also remains uncertain. FDA reviews can require additional information, potentially delaying product launches and increasing development costs.

Competition in optical imaging and medical technology markets remains significant, with adoption dependent not only on technical performance but also clinician acceptance, workflow integration and commercial economics.

What Investors Should Watch Next

Investors will focus on whether Optiscan can transition from development milestones into measurable commercial progress.

Key areas to monitor include:

• Revenue contribution from the InSpecta veterinary launch.

• FDA progress on the InSpecta regulatory review.

• Confirmation of InVue and InForm 510(k) submission timelines.

• Clinical study recruitment and results from ongoing programs.

• Changes in cash usage as commercial activities expand.

Conclusion

Optiscan Imaging has entered a critical phase as it attempts to transform its confocal laser endomicroscopy technology from a research platform into commercial medical and veterinary products.

The launch of InSpecta in the US veterinary market represents an important commercial milestone, while upcoming FDA submissions for InVue and InForm could determine the company’s longer-term healthcare opportunity.

However, the company remains in a development phase, with limited revenue, ongoing losses and regulatory hurdles still ahead. Future value creation will depend on successful approvals, customer adoption and evidence that the technology can generate repeat commercial sales.